Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)
Immunome shares surged after its Phase 3 RINGSIDE trial showed varegacestat cut the risk of desmoid tumor progression or death by 84% versus placebo (hazard ratio 0.16; p